ID

Question 1

Answer 1

Question 2

HSV encephalitis test

Answer 2

HSV PCR

Question 3

West Nile Neuroinvasive Disease Test

Answer 3

Serum and CSF IgM

Question 4

Answer 4

Question 5

Answer 5

Question 6

Answer 6

Question 7

Answer 7

Question 8

Answer 8

Question 9

Answer 9

Question 10

Treatment for Lyme Disease

Answer 10

Question 11

Babesia treatment

Answer 11

Question 12

UTI treatment (complicated/pregnant)

Answer 12

Question 13

Answer 13

Question 14

TB treatment

Answer 14

Question 15

Treatment of MAC

Answer 15

Question 16

Treatment for Aspergillosis

Answer 16

Question 17

Treatment for Candida

Answer 17

Question 18

Treatment of Cryptococcus

Answer 18

Question 19

Answer 19

Question 20

Treatment of gonnorrhea/chlamydia

Answer 20

Question 21

Treatment of PID

Answer 21

Question 22

Treatment of Syphyllis

Answer 22

Question 23

HPV treatment

Answer 23

Question 24

Testing for complement deficiency

Answer 24

Question 25

Answer 25

Question 26

Anthrax Treatment

Answer 26

Question 27

Tularemia Treatment

Answer 27

Question 28

Malaria Prevention

Answer 28

Question 29

Answer 29

Question 30

Transplant Infections

Answer 30

Question 31

Transplant Infection treatment

Answer 31

Question 32

Catheter Assoicated Infection Treatment

Answer 32

Question 33

HIV post-exposure prophylaxis

Answer 33

Question 34

Answer 34

Question 35

PJP treatment

Answer 35

Question 36

Toxoplosmosis Treatment

Answer 36

Question 37

EBV symptoms

Answer 37

Question 38

Possible vs probable or confirmed encephalitis criteria

Answer 38

Possible: one major nd two minor criteria

probable or confirmed: one major and at least three minor criteria.

Major: altered consciousness for more than 24 hours

minor: fever, new-onset seizure, new-onset focal neurologic findings, CSF pleocytosis, and abnormal MRI or electroencephalographic finding

Question 39

complicated UTI definitions (x7)

Answer 39

UTIs in men, pregnant women, and persons with foreign bodies (for example, indwelling catheters, calculi), kidney disease, immunocompromise, obstruction, urinary retention from neurologic disorders, health care–associated infections, or recent antibiotic use are considered to be complicated.

Question 40

evaluation of classic FUO

Answer 40

complete blood count with differential, electrolyte levels, kidney and liver function tests (hepatitis serology if results are abnormal), lactate dehydrogenase level, urinalysis or microscopy and urine culture, erythrocyte sedimentation rate, C-reactive protein, antinuclear antibodies, rheumatoid factor, HIV testing, cytomegalovirus polymerase chain reaction testing, blood cultures (three sets, each set obtained at least several hours apart), tuberculosis testing, and chest radiography (or chest CT). Q-fever serology should be considered if risk factors exist, and mycobacterial blood cultures should be obtained in HIV-positive patients with CD4 cell counts of 50/µL or less.

If initial tests do not suggest a cause, abdominal or pelvic CT may be considered to evaluate for intra-abdominal abscess or lymphoproliferative disorders.

Question 41

P. Falciparum morphology on smear

Answer 41

Question 42

Malaria resistent to chloroquine

Answer 42

P. vivax

P. falciparum

P. malariae(rare)

Question 43

Treatment of Cryptosporidium

Answer 43

supportive care for most immunocompetent hosts; nitazoxanide is recommended for severe or prolonged infection or if supportive care does not resolve symptoms; antiretroviral therapy is most effective in resolving infection in HIV-infected patients.

Question 44

Cyclospora Treatment

Answer 44

Bactrim

Question 45

Entamoeba histolytica treatment

Answer 45

metronidazole or tinidazole is recommended initially for parasitic clearance followed by an intraluminal amebicide, such as paromomycin or diloxanide

Question 46

risk factors for antibiotic resistance

Answer 46

previous intravenous antibiotics within 90 days, septic shock at the time of VAP diagnosis, acute respiratory distress syndrome preceding VAP, 5 or more days of hospitalization before developing VAP, and dialysis before VAP onset.